Clinical Relevance of Donor-Derived cfDNA In Monitoring Kidney Transplant Rejection
Authors:
- Angelica PagliazziAPAngelica Pagliazzi
- Karolien WellekensKWKarolien Wellekens
- Henriette de LoorHLHenriette de Loor
- Priyanka KoshyPKPriyanka Koshy
- Thibaut VauletTVThibaut Vaulet
- Arthur VrankenAVArthur Vranken
- Thomas VanhoutteTVThomas Vanhoutte
- Dirk KuypersDKDirk Kuypers
- Borefore JallahBJBorefore Jallah
- Robert WoodwardRWRobert Woodward
- 14 May 2026
- journal article
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (10) , 2262-2274
Abstract
Background: Over the past 25 years, donor-derived cell-free DNA (dd-cfDNA) has emerged as a noninvasive biomarker for detecting allograft rejection in kidney transplant recipients, yet its clinical interpretability and context(s) of use in post-transplant monitoring remain largely unexplored. Methods: In this observational cohort study, we analyzed 472 retrospective and 450 prospective plasma samples as the derivation and validation cohorts, respectively. Samples were collected at the time of either an indication or a protocol kidney biopsy. We evaluated three logistic regression models for rejection discrimination: a clinical model, the dd-cfDNA alone, and their combination. Result-specific likelihood ratios (LR) were derived from the dd-cfDNA-based model probabilities and applied to the clinical model predictions to obtain post-test probabilities of rejection. By comparing pre- and post-test probabilities, we assessed the impact of dd-cfDNA on rejection risk stratification. Results: Dd-cfDNA alone demonstrated strong discriminative ability, with AUCs of 0.79 (95% CI: 0.73–0.84) and 0.80 (95% CI: 0.72–0.87) in the derivation and validation cohorts, respectively. Combining dd-cfDNA with clinical parameters improved the above AUCs to 0.82 and 0.87, respectively. We compared pre- and post-test probabilities to determine how dd-cfDNA testing influenced rejection risk estimation. Incorporating dd-cfDNA-testing results clarified risk stratification by reducing the number of samples categorized as intermediate (10-30%) pre-test risk. Overall, 253/345 pre-test intermediate risk samples were reclassified, with 117/162 (72%) and 33/91 (36%) correctly assigned to low (≤10%) and high (≥30%) post-test risk, respectively. With 10% probability threshold for warranting a kidney biopsy, 482 biopsies would have been safely avoided using post-test probabilities, with 437 (91%) of these being protocol biopsies. Conclusions: Our study confirmed the strong association between dd-cfDNA% and rejection after kidney transplantation. Using test result-specific likelihood ratio, we evaluated the impact of integrating dd-cfDNA% for estimating time-point-specific rejection risk, demonstrating its potential to reduce the number of unnecessary biopsies in a cohort with a relatively low rejection prevalence.Keywords
Funding Information
- FWO (1S93025N)
- FWO (11P1524N)
- FWO (12D6423N)
- FWO (1844024N)
This publication has 27 references indexed in Scilit:
- Continuous indices to assess the phenotypic spectrum of kidney transplant rejectionNature Communications, 2025
- The impact of the Banff v-lesion on rejection classification and outcomes: Insights from a multicenter studyAmerican Journal of Transplantation, 2025
- Simply measuring what matters—toward clinical utility of donor-derived cell-free DNA testing?Kidney International, 2025
- Probable antibody-mediated rejection in kidney transplantation is a rare and challenging phenotype to define: Findings from a single-center studyAmerican Journal of Transplantation, 2024
- Cell-free DNA for the detection of kidney allograft rejectionNature Medicine, 2024
- From autoantibody test results to decision making: Incorporating likelihood ratios within medical practiceAutoimmunity Reviews, 2024
- The Banff 2022 Kidney Meeting Report: Reappraisal of microvascular inflammation and the role of biopsy-based transcript diagnosticsAmerican Journal of Transplantation, 2023
- Clinical outcomes from the Assessing Donor-derived cell-free DNA Monitoring Insights of kidney Allografts with Longitudinal surveillance (ADMIRAL) studyKidney International, 2022
- Refining clinical diagnosis with likelihood ratiosThe Lancet, 2005
- Presence of donor-specific DNA in plasma of kidney and liver-transplant recipientsThe Lancet, 1998